Archived formalin-fixed paraffin-embedded (FFPE) specimens from nonmalignant tissues derived from cancer patients are a vast and potentially valuable resource for high-quality genotyping analyses and could have a role in establishing inherited cancer risk.
Methods:
We systematically searched PubMed, Ovid MEDLINE, and Scopus databases for all articles that compared genotyping performance of DNA from nonmalignant FFPE tissue with blood DNA derived from cancer patients irrespective of tumor type. Two independent researchers screened the retrieved studies, removed duplicates, excluded irrelevant studies, and extracted genotyping data from the eligible studies. These studies included, but were not limited to, genotyping technique, reported call rate, and concordance.
Results:
Thirteen studies were reviewed, in which DNA from nonmalignant FFPE tissues derived from cancer patients was successfully purified and genotyped. All these studies used different approaches for genotyping of DNA from nonmalignant FFPE tissues to amplify single nucleotide polymorphisms (SNPs) and to estimate of loss of heterozygosity. The concordance between genotypes from nonmalignant FFPE tissues and blood derived from cancer patients was observed to be high, whereas the call rate of the tested SNPs was not reported in all included studies.
Conclusion:
This review illustrates that DNA from nonmalignant FFPE tissues derived from cancer patients can serve as an alternative and reliable source for assessment of germline DNA for various purposes, including assessment of cancer predisposition.
Get full access to this article
View all access options for this article.
References
1.
AgarwalD, NowakC, ZhangNR, et al.Functional germline variants as potential co-oncogenes. NPJ Breast Cancer, 2017; 3:46.
2.
MichailidouK, HallP, Gonzalez-NeiraA, et al.Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet, 2013; 45:353–361, 361e1–362.
3.
AgarwalD, PinedaS, MichailidouK, et al.FGF receptor genes and breast cancer susceptibility: Results from the Breast Cancer Association Consortium. Br J Cancer, 2014; 110:1088–1100.
4.
EmamiNC, LeongL, WanE, et al.Tissue sources for accurate measurement of germline DNA genotypes in prostate cancer patients treated with radical prostatectomy: Comparison of normal tissue genotypes. Prostate, 2017; 77:425–434.
5.
KaurRP, ShafiG, BenipalRPS, et al.Frequency of pathogenic germline mutations in cancer susceptibility genes in breast cancer patients. Med Oncol, 2018; 35:81.
6.
NaR, WuY, JiangG, et al.Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis. BJU Int, 2018; 122:808–813.
7.
Gillio-TosA, De MarcoL, FianoV, et al.Efficient DNA extraction from 25-year-old paraffin-embedded tissues: Study of 365 samples. Pathology, 2007; 39:345–348.
8.
GilbertMTP, HaselkornT, BunceM, et al.The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when?. PLoS One, 2007; 2:e537.
9.
LenzeD, MüllerH-H, HummelM. Considerations for the use of formalin-fixed and paraffin-embedded tissue specimens for clonality analysis. J Hematop, 2012; 5:27–34.
10.
SikoraMJ, ThibertJN, SalterJ, et al.High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues. Pharmacogenomics J, 2011; 11:348–358.
11.
RobbeP, PopitschN, KnightSJL, et al.Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: Pilot study for the 100,000 Genomes Project. Genet Med, 2018; 20:1196–1205.
12.
VanderLaanPA, YamaguchiN, FolchE, et al.Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer, 2014; 84:39–44.
13.
CannataroVL, GaffneySG, TownsendJP. Effect sizes of somatic mutations in cancer. J Natl Cancer Inst, 2018; 110:1171–1177.
14.
GoetzMP, RaeJM, SumanVJ, et al.Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol, 2005; 23:9312–9318.
15.
MarisiG, PassardiA, CalistriD, et al.Discrepancies between VEGF −1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue. Int J Mol Sci, 2014; 15:13333–13343.
16.
RoukosDH. Genome-wide association studies: How predictable is a person's cancer risk?. Expert Rev Anticancer Ther, 2009; 9:389–392.
17.
ChoJH. Genome-wide association studies: Present status and future directions. Gastroenterology, 2010; 138:1668.e1–1672.e1.
18.
MavaddatN, MichailidouK, DennisJ, et al.Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet, 2019; 104:21–34.
19.
LällK, LepametsM, PaloverM, et al.Polygenic prediction of breast cancer: Comparison of genetic predictors and implications for risk stratification. BMC Cancer, 2019; 19:557.
20.
MarsN, KoskelaJT, RipattiP, et al.Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat Med, 2020; 26:549–557.
21.
DaiJ, LvJ, ZhuM, et al.Identification of risk loci and a polygenic risk score for lung cancer: A large-scale prospective cohort study in Chinese populations. Lancet Respir Med, 2019; 7:881–891.
22.
MoherD, LiberatiA, TetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ, 2009; 339:b2535.
23.
GuyattG, OxmanAD, AklEA, et al.GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 2011; 64:383–394.
24.
XieB, FreudenheimJL, CummingsSS, et al.Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer. Carcinogenesis, 2006; 27:307–310.
25.
RaeJM, ReganMM, ThibertJN, et al.Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst, 2013; 105:1332–1334.
26.
HertzDL, KidwellKM, ThibertJN, et al.Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol, 2015; 9:1868–1876.
27.
AdankMA, BrogiE, BogomolniyF, et al.Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. Fam Cancer, 2006; 5:337–342.
28.
LipsEH, DierssenJWF, van EijkR, et al.Reliable high-throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism arrays. Cancer Res, 2005; 65:10188–10191.
29.
ZauberNP, Sabbath-SolitareM, MarottaSP, et al.Comparison of allelic ratios from paired blood and paraffin-embedded normal tissue for use in a polymerase chain reaction to assess loss of heterozygosity. Mol Diagn, 1999; 4:29–35.
30.
HagleitnerMM, CoenenMJH, JeukenJWM, et al.Taqman genotyping assays can be used on decalcified and paraffin-embedded tissue from patients with osteosarcoma. Pediatr Blood Cancer, 2011; 56:35–38.
31.
VosHI, van der StraatenT, CoenenMJH, et al.High-quality genotyping data from formalin-fixed, paraffin-embedded tissue on the drug metabolizing enzymes and transporters plus array. J Mol Diagn, 2015; 17:4–9.
32.
Cannon-AlbrightLA, CooperKG, GeorgelasA, BernardPS. High quality and quantity genome-wide germline genotypes from FFPE normal tissue. BMC Res Notes, 2011; 4:159.
33.
SjöholmMIL, HoffmannG, LindgrenS, et al.Comparison of archival plasma and formalin-fixed paraffin-embedded tissue for genotyping in hepatocellular carcinoma. Cancer Epidemiol Biomark Prev, 2005; 14:251–255.
34.
GuoM, YueW, SamuelsDC, et al.Quality and concordance of genotyping array data of 12,064 samples from 5840 cancer patients. Genomics, 2019; 111:950–957.
35.
WilliamsC, PonténF, MobergC, et al.A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol, 1999; 155:1467–1471.
36.
DoH, DobrovicA. Sequence artifacts in DNA from formalin-fixed tissues: Causes and strategies for minimization. Clin Chem, 2015; 61:64–71.
37.
McDonoughSJ, BhagwateA, SunZ, et al.Use of FFPE-derived DNA in next generation sequencing: DNA extraction methods. PLoS One, 2019; 14:e0211400.
38.
BerraCM, TorrezanGT, de PaulaCA, et al.Use of uracil-DNA glycosylase enzyme to reduce DNA-related artifacts from formalin-fixed and paraffin-embedded tissues in diagnostic routine. Appl Cancer Res, 2019; 39:7.
39.
EllervikC, VaughtJ. Preanalytical variables affecting the integrity of human biospecimens in biobanking. Clin Chem, 2015; 61:914–934.
40.
PerreaultLP, LegaultMA, BarhdadiA, et al.Comparison of genotype clustering tools with rare variants. BMC Bioinformatics, 2014; 15:52.
41.
GuoQ, WangJ, XiaoJ, et al.Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Mol Cancer, 2018; 17:131.
42.
HornH, PottC, KallaJ, et al.A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens. Pharmacogenet Genomics, 2010; 20:598–604.
43.
van Huis-TanjaL, KweekelD, GelderblomH, et al.Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. Pharmacogenomics, 2013; 14:2005–2012.
44.
JasmineF, AhsanH, AndrulisIL, et al.Whole genome amplification enables accurate genotyping for microarray-based high density SNP array. Cancer Epidemiol Biomark Prev, 2008; 17:3499–3508.
45.
DagnallCL, MortonLM, HicksBD, et al.Successful use of whole genome amplified DNA from multiple source types for high-density Illumina SNP microarrays. BMC Genomics, 2018; 19:182.
46.
KruhøfferM, VossT, BellerK, et al.Evaluation of the QIAsymphony SP Workstation for magnetic particle–based nucleic acid purification from different sample types for demanding downstream applications. J Assoc Lab Autom, 2010; 15:41–51.
47.
FrazerZ, YooC, SroyaM, et al.Effect of different proteinase k digest protocols and deparaffinization methods on yield and integrity of DNA extracted from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem, 2020; 68:171–184.
48.
BonnetE, MoutetM-L, BaulardC, et al.Performance comparison of three DNA extraction kits on human whole-exome data from formalin-fixed paraffin-embedded normal and tumor samples. PLoS One, 2018; 13:e0195471.
49.
Lyons-WeilerM, HagenkordJ, SciulliC, et al.Optimization of the affymetrix genechip mapping 10k 2.0 assay for routine clinical use on formalin-fixed paraffin-embedded tissues. Diagn Mol Pathol, 2008; 17:3–13.
